Carbiotix reports positive results from FoodMarble study
Carbiotix (publ) ("Carbiotix") announces today positive results from an eight-week study with FoodMarble Digestive Health Ltd. (“FoodMarble”) of Dublin, a leading provider of connected digestive health devices, to examine the correlation between digestive health and gut health. Carbiotix and FoodMarble will now enter into discussions regarding next steps for the further development of their combined technologies.
An eight-week cross-over study was conducted during Q4 2019 in Ireland with twenty individuals using two different prebiotic fiber interventions (GOS and Wheat Dextrin) and a two-week wash-out period between interventions. The collaborative goal of the study was to examine the correlation between digestive health, measured in terms of hydrogen gas (H2) production using the FoodMarble AIRE device, and gut health, measured by conducting a 16s Next Generation Sequencing (NGS) analysis of faecal samples from study subjects at Carbiotix in Lund. The study showed that Bifidobacterium (a hallmark of gut health) was significantly positively correlated with changes in breath hydrogen.
Kristofer Cook, CEO for Carbiotix, comments
“These results, although preliminary, are very important for Carbiotix and have the potential to directly impact the success of both our gut health diagnostic platform and therapeutic interventions. The indirect measurement of gut health leveraging platforms such as the FoodMarble AIRE will allow for the realtime dosing and personalisation of interventions, which will be a decisive factor impacting the efficacy and competitiveness of a gut health intervention given the variable nature of the gut microbiome.”
Aonghus Shortt, CEO for Food Marble, comments
“The results from this study are extremely encouraging, indicating that breath analysis and microbiome sequencing potentially have a complementary role in identifying beneficial gut microbiome compositional changes, in response to prebiotic treatment."
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company’s contact person set out below on 12 March 2020.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release
For further information:
Kristofer Cook, CEO
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.